β-Cell–Specific Protein Kinase A Activation Enhances the Efficiency of Glucose Control by Increasing Acute-Phase Insulin Secretion
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Acute insulin secretion determines the efficiency of glucose clearance. Moreover, impaired acute insulin release is characteristic of reduced glucose control in the prediabetic state. Incretin hormones, which increase β-cell cAMP, restore acute-phase insulin secretion and improve glucose control. To determine the physiological role of the cAMP-dependent protein kinase (PKA), a mouse model was developed to increase PKA activity specifically in the pancreatic β-cells. In response to sustained hyperglycemia, PKA activity potentiated both acute and sustained insulin release. In contrast, a glucose bolus enhanced acute-phase insulin secretion alone. Acute-phase insulin secretion was increased 3.5-fold, reducing circulating glucose to 58% of levels in controls. Exendin-4 increased acute-phase insulin release to a similar degree as PKA activation. However, incretins did not augment the effects of PKA on acute-phase insulin secretion, consistent with incretins acting primarily via PKA to potentiate acute-phase insulin secretion. Intracellular calcium signaling was unaffected by PKA activation, suggesting that the effects of PKA on acute-phase insulin secretion are mediated by the phosphorylation of proteins involved in β-cell exocytosis. Thus, β-cell PKA activity transduces the cAMP signal to dramatically increase acute-phase insulin secretion, thereby enhancing the efficiency of insulin to control circulating glucose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“GLP-1 also activates the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway, which is crucial for maintaining the survival and function of pancreatic β-cells.184–187”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [184]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132 · cited 1×
“The PKA inhibitors H89 and KT5720 inhibit a number of other kinases with similar or greater efficacy than PKA (37).”
BackgroundKahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405
Low access resistance perforated patch recordings using amphotericin B
Rae, J., Cooper, K., Gates, P., & Watsky, M. (1991) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(91)90017-t · Cited by 917 · cited 1×
“Patch electrodes were used as previously described (23) to record b-cells identified by a resting membrane”
MethodBagdade, J. D., Bierman, E. L., & Porte, D. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105646 · Cited by 672
Dynamics of Insulin Secretion by the Perfused Rat Pancreas
CURRY, D. L., BENNETT, L. L., & GRODSKY, G. M. (1968) · Endocrinology · doi:10.1210/endo-83-3-572 · Cited by 601 · cited 1×
“Glucose-stimulated insulin release is biphasic, characterized by an initial acute burst of insulin secretion followed by a sustained suprabasal release of insulin (1,2).”
BackgroundAbnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.
Polonsky, K. S., Given, B. D., Hirsch, L. J., Tillil, H., Shapiro, E. T., Beebe, C., Frank, B. H., Galloway, J. A., & Van Cauter, E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181903 · Cited by 567 · cited 1×
“Progression to type 2 diabetes is characterized by a loss in b-cell function, a critical feature of which is reduced acutephase insulin release (32,33).”
BackgroundPKA-Dependent and PKA-Independent Pathways for cAMP-Regulated Exocytosis
Seino, S., & Shibasaki, T. (2005) · Physiological Reviews · doi:10.1152/physrev.00001.2005 · Cited by 563 · cited 5×
“The EPAC-specific cAMP analog, 8-pCPT-29-O-MecAMP, also activates PKA, albeit with a 10-fold higher Kd than EPAC in cell free assays.”
BackgroundInfluentialBRUNZELL, J. D., ROBERTSON, R. P., LERNER, R. L., HAZZARD, W. R., ENSINCK, J. W., BIERMAN, E. L., & PORTE, D. (1976) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-42-2-222 · Cited by 505 · cited 1×
“Progression to type 2 diabetes is characterized by a loss in b-cell function, a critical feature of which is reduced acutephase insulin release (32,33).”
BackgroundThiebaud, D., Jacot, E., Defronzo, R. A., Maeder, E., Jequier, E., & Felber, J.-P. (1982) · Diabetes · doi:10.2337/diacare.31.11.957 · Cited by 489 · cited 2×
“This phase of insulin release, however, is absolutely critical in determining the efficiency of blood glucose clearance and does so by increasing the transendothelial transportation of insulin into skeletal muscle, where up to 80% of glucose uptake occurs (5).”
BackgroundEpac: Defining a New Mechanism for cAMP Action
Gloerich, M., & Bos, J. L. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105714 · Cited by 473 · cited 1×
“In addition, 8-pCPT-29-O-MecAMP inhibits phosphodiesterases 1, 2, and 6, and so this can increase cAMP and cGMP levels (38,39).”
Background
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Targeting cAMP/PKA pathway for glycemic control and type 2 diabetes therapy
Yang, H., & Yang, L. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0316 · Cited by 203
Navarro, G., Xu, W., Jacobson, D. A., Wicksteed, B., Allard, C., Zhang, G., De Gendt, K., Kim, S. H., Wu, H., Zhang, H., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.03.015 · Cited by 171
“Consistent with AR signaling via a PKA pathway, transgenic mice with enhanced PKA catalytic activity in pancreatic islets (Kaihara et al., 2013; Song et al., 2011) exhibit increased GSIS but, like male bARKO /y mice, show no change in b cell mass or insulin synthesis.”
Self-citationSmith, E. P., An, Z., Wagner, C., Lewis, A. G., Cohen, E. B., Li, B., Mahbod, P., Sandoval, D., Perez-Tilve, D., Tamarina, N., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.04.005 · Cited by 164
“Transgenic Lines The MIPcreER line generation has been previously described (Kaihara et al., 2013; Wicksteed et al., 2010) with more characterization in the Supplemental Information (see also Figure S2 and Figure S2 legend).”
MethodSelf-citation
Metadata
- Authors
- Kaihara, K. A., Dickson, L. M., Jacobson, D. A., Tamarina, N., Roe, M. W., Philipson, L. H., & Wicksteed, B.
- Affiliations
- University of Chicago (US)
- Vanderbilt University (US)
- SUNY Upstate Medical University (US)
- Corresponding author
- Wicksteed, Barton
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-04-16
- Volume
- 62
- Issue
- 5
- Pages
- 1527-1536
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3636652
- OpenAlex
- W2143340315
- Cited by
- 80
- References
- 51
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 6 · 2023: 6 · 2022: 4 · 2021: 8 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 7 · 2015: 9 · 2014: 12 · 2013: 3
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association (1-08-JF-58)
- McKnight Foundation
- University of Washington
- National Institutes of Health (5t32dk087703-05, DK020595, DK063493)
- Diabetes Research and Training Center (DK020595)
- National Institute on Aging (F31AG035620)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK087703, DK-063493, R01DK048494, DK074966, R01DK085129, R01DK063493, T32-DK-087703, DK020595, DK-085129, DK-48494, R01DK092616, R01DK074966, P60DK020595, P30DK020595)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- cAMP signaling, sustained insulin release, glycemic control, prediabetes, incretins, exendin-4, hyperglycemia, pancreatic beta cells, glucose clearance
- MeSH terms
- Exenatide, Insulin Secretion, Cyclic AMP, Animals, Crosses, Genetic, Enzyme Induction, Hyperglycemia, Hypoglycemic Agents, Insulin, Kinetics, Peptides, Phosphorylation, Protein Processing, Post-Translational, Venoms, Second Messenger Systems, Glucose Clamp Technique, Up-Regulation, Cyclic AMP-Dependent Protein Kinases, Patch-Clamp Techniques, Protein Subunits, Insulin-Secreting Cells, Mutant Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.